sábado, 6 de octubre de 2018

Canadian advisory group: Vertex cystic fibrosis drug isn't worth covering - STAT

Canadian advisory group: Vertex cystic fibrosis drug isn't worth covering - STAT

Daily Recap

STAT Plus: A Canadian advisory group says a Vertex cystic fibrosis drug isn’t worth covering

By ED SILVERMAN


CRAIG F. WALKER/THE BOSTON GLOBE
The Canadian Agency for Drugs and Technologies in Health raised doubt over clinical trials measuring the extent to which the drug improved patient health.

No hay comentarios: